Streetbeat News

Stock Prices

ICCM

IceCure Medical has received a Nasdaq minimum bid price notification. This means that the company's stock has not met the minimum bid price of $1.00 per share for 30 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:07 pm

ELWS

Earlyworks has received a notification from Nasdaq regarding a minimum bid price deficiency. The company's stock, ELWS, is currently not meeting the minimum bid price requirement set by Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:05 pm

KA

Kineta's Q3 2023 earnings per share (EPS) was $(0.46), up from $(1.14) YoY. The company's cash position decreased to $7.6 million from $13.1 million due to clinical trial development and general corporate purposes. However, this was offset by $5.5 million net proceeds from a direct offering and $5.0 million from a Merck milestone payment. Total revenues were zero for Q3 2023, compared to $0.2 million for Q3 2022. R&D expenses decreased, while general and administrative expenses increased due to higher personnel-related costs.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:04 pm

AAPL

AMD

LLY

NVO

QCOM

The Federal Reserve held interest rates steady, soothing investors and sparking a market rally. Robust earnings reports also boosted investor sentiment. The labor market showed signs of softening, with job gains slowing and unemployment rising. Apple, Advanced Micro Devices, and Qualcomm outperformed expectations, while Novo Nordisk and Eli Lilly beat estimates. Upcoming earnings reports from Vertex Pharmaceuticals, Gilead Sciences, Uber Technologies, Occidental Petroleum, Walt Disney, and Becton Dickinson will be closely watched.

Portfolio Pulse from Piero Cingari

November 03, 2023 | 8:03 pm

GHM

Graham (NYSE:GHM) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $-0.04. The company's past performance shows it beat EPS estimates last quarter, resulting in a 1.96% increase in share price. Shares of Graham were trading at $16.81 as of November 2, with a 52-week increase of 83.48%.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:02 pm

AQST

Aquestive Therapeutics (NASDAQ:AQST) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $-0.11. The company's stock price has historically been affected more by its guidance than its earnings performance. Last quarter, the company beat EPS by $0.01, resulting in a 5.37% drop in the share price the next day. Over the last 52-week period, shares are up 69.66%.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:02 pm

NSPR

InspireMD (NASDAQ:NSPR) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $-0.15. The company's past performance shows a pattern of beating EPS estimates. The stock price, however, does not always correlate with earnings beats or misses, but often with the company's guidance. Shares of InspireMD are currently trading at $3.34 and have seen a 213.89% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:01 pm

ALTO

Alto Ingredients (NASDAQ:ALTO) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $0.09. The company's past performance shows it beat EPS by $0.17 last quarter, leading to a 17.52% increase in share price the next day. The stock was trading at $4.45 as of November 2, with a 52-week increase of 11.12%.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:01 pm

AUGX

Augmedix (NASDAQ:AUGX) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $-0.12. The company's past performance shows a pattern of share price changes following earnings reports. Shares of Augmedix were trading at $4.56 as of November 2, with a 235.19% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:01 pm

FENC

Fennec Pharmaceuticals (NASDAQ:FENC) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $-0.11. The company's past performance shows a pattern of EPS misses, with the last quarter missing by $0.05. The share price increased by 0.25% the next day. The company's shares were trading at $6.96 as of November 2, with a 52-week decrease of 18.54%.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:01 pm